MarcusYoung Huisheng Biotechnology At IPEMA-Hybiz.tv MarcusYoung Huisheng Biotechnology At IPEMA-Hybiz.tv Watch More Business Videos at Indias Leading online business channel Hybiz TV Like us on Facebook: h... By: hybiztv … Continue reading →

BioCareer Capsule 1: Food Biotechnology Cosmeceutical By: BiotechCorpMy … Continue reading →

A policy forum on strengthening biotechnology research and development in the country was held last November 27 at the CHED Auditorium in Diliman, Quezon City. Hosted by the Department of Agricultures Biotechnology Program Office, speakers at the forum tackled policy issues and institutional challenges that the Philippines faces in pursuit of solutions for food security concerns. According to Dr. Saturnina Halos, Director of Research at the Biotechnology Coalition of the Philippines, the country lacks a critical mass of researchers. We only have 100 full-time equivalent researchers per 1 million of the the population, the lowest ratio among Asia Pacific countries. One of the factors that may contribute to this lack of researchers is the fact that many researchers are simply on contract, prompting them to leave in search of better job conditions. And while many universities require research output from their faculty, faculty members need to look for their own funding. Meanwhile Mariechel Navarro, Director of the Global Knowledge Center on Crop Biotechnology at the International Service for the Acquisition of Agri-Biotech Applications (ISAAA) emphasized that if we want to get the public to accept biotechnology, we need to change the way that the information gets to them via the … Continue reading →

NEW YORK Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Puma Biotechnology Inc. (PBYI), down $27.33 to $197.67 The biotechnology company said it will delay filing for marketing approval until 2016 for an experimental breast cancer drug. Abercrombie & Fitch Co. (ANF), up 97 cents to $28.81 The clothing and apparel retailer reported better-than-expected quarterly profit, but its revenue fell short of forecasts. Cliffs Natural Resources Inc. (CLF), up 44 cents to $8.60 The mining company is selling off coal assets in West Virginia as it continues to shift more toward being an iron ore supplier. Transocean Ltd. (RIG), up 19 cents to $19.57 The offshore drilling services company and its peers saw shares rise as oil prices rose slightly following a period of decline. See more here: Puma Biotechnology, Cliffs are big market movers … Continue reading →

Shares of Puma Biotechnology, Inc. ( PBYI ) were down in after-market hours trading following the company's announcement that the New Drug Application (NDA) for its pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016. We remind investors that Puma Biotechnology had earlier announced that the NDA will be filed in the first half of 2015 based on the feedback it had previously received from regulatory agencies. It had mainly focused on the proposed clinical indication of HER2-positive metastatic breast cancer. However, the company's initial NDA filing will now include the extended adjuvant HER2-positive early-stage breast cancer indication. Consequently, Puma Biotechnology will need to submit data from preclinical carcinogenicity studies with its NDA filing, as per the International Conference on Harmonization guidelines, pushing the deadline to 2016. We note that Puma Biotechnology has a licensing agreement with Pfizer ( PFE ) for neratinib. Our Take Puma Biotechnology carries a Zacks Rank #4 (Sell). The delay in the NDA filing is quite disappointing as the company has no approved products and neratinib is its lead pipeline candidate. This will consequently delay the potential approval, thereby impacting Puma Biotechnology's growth prospects. Last month, the company announced disappointing top-line … Continue reading →